Resource Summary Report

Generated by RRID on Sep 8, 2026

CD97 antibody [EPR4427]

RRID:AB_10865208
Type: Antibody

Proper Citation

Abcam Cat# ab108368, RRID:AB_10865208

Antibody Information

URL: http://antibodyregistry.org/AB_10865208

Proper Citation: Abcam Cat# ab108368, RRID:AB_10865208

Target Antigen: CD97 antibody [EPR4427]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: ICC, IHC-P, IP, WB; Immunohistochemistry; Immunoprecipitation; Immunocytochemistry; Immunohistochemistry - fixed; Western Blot

Antibody Name: CD97 antibody [EPR4427]

Description: This monoclonal targets CD97 antibody [EPR4427]

Target Organism: mouse, human

Antibody ID: AB_10865208

Vendor: Abcam

Catalog Number: ab108368

Record Creation Time: 20231110T064037+0000

Record Last Update: 20260829T045951+0000

Ratings and Alerts

No rating or validation information has been found for CD97 antibody [EPR4427].

No alerts have been found for CD97 antibody [EPR4427].

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Wang J, et al. (2026) Adipocyte-derived extracellular vesicles are key regulators of central leptin sensitivity and energy homeostasis. Cell metabolism, 38(1), 82.

Zhou S, et al. (2024) CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells. Cell reports. Medicine, 5(12), 101844.

Garofano K, et al. (2023) Prostate cancer cell-platelet bidirectional signaling promotes calcium mobilization, invasion and apoptotic resistance via distinct receptor-ligand pairs. Scientific reports, 13(1), 2864.

Ravn-Boess N, et al. (2023) The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability. Cell reports, 42(11), 113374.